Skip to main content

Alpha-synuclein Post-translational Modification Quantification Program


This program seeks to establish robust methods and tools that can quantify the amount and regional distribution of post-translational modifications of alpha-synuclein in Parkinson’s disease-relevant brain regions.

Funding will support projects aimed to:  

  • Develop, characterize, and validate assays to accurately detect and quantify alpha-synuclein post-translational modifications (PTMs) reliably  

  • Optimize and refine reproducible protocols for the isolation of alpha-synuclein (soluble/insoluble) species from brain tissues and inclusions that preserve its biochemical diversity  

  • Use reproducible methods to develop quantitative maps of alpha-synuclein post-translational modifications in disease-relevant brain regions 

  • Utilize new technologies and/or cutting-edge methods to address previously intractable roadblocks 

When considering proposals submitted to this program, MJFF will prioritize projects and teams that: 

  • Have previously demonstrated success with techniques and technologies proposed for use 

  • Have assembled cross-disciplinary teams with relevant expertise  

  • Have access to post-mortem brain tissue containing relevant brain regions from subjects with Parkinson’s and age-matched controls 

  • Proposed the use of techniques and technologies that can be easily deployed in other laboratories 

  • Proposed the quantification of alpha-synuclein post-translational modifications across multiple stages of the disease  

  • Show willingness to collaborate with other teams and stakeholders for this program  

For this round, MJFF will not consider:  

  • Assessments of alpha-synuclein post-translational modifications in biofluids or non-CNS tissues.  

  • The study of alpha-synuclein post-translational modifications in pre-clinical or cellular models of Parkinson’s disease 

  • Purely qualitative assessments of alpha-synuclein post-translational modifications present in human brain tissue  

  • Development of antibodies or nanobodies toward alpha-synuclein post-translational modifications 

Email with questions.  

Watch a video on this funding program that covers our application and review processes. 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.